Glucoză Zentiva (Glucose Monohydrate)

Glucoză Zentiva is indicated for several clinical situations where rapid delivery of glucose is required.

• Treatment of documented hypoglycemia in patients who are unable to ingest oral carbohydrates, providing rapid rise in plasma glucose.
• Provision of caloric support as part of total parenteral nutrition regimens, helping meet daily energy requirements when enteral feeding is not feasible.
• Fluid and electrolyte replacement when combined with appropriate electrolyte solutions, assisting in the correction of dehydration and maintenance of osmolar balance.
• Maintenance of blood glucose levels during surgical procedures or intensive care monitoring, reducing the risk of intra‑operative hypoglycemia.
• Support for patients with metabolic disorders that limit endogenous glucose production, such as glycogen storage diseases or severe liver dysfunction.

When administered intravenously, Glucoză Zentiva may be associated with a range of observed effects, most of which are mild and transient.

Common

• Mild hyperglycemia that resolves without intervention.
• Transient nausea or vomiting related to rapid glucose infusion.
• Local irritation or mild pain at the injection site.
• Slight increase in serum sodium due to osmotic shift.
• Temporary feeling of warmth or flushing during infusion.

Serious

• Severe hyperglycemia leading to osmotic diuresis or electrolyte imbalance.
• Allergic or anaphylactic reaction presenting with rash, itching, bronchospasm, or hypotension.
• Hyperosmolar hyperglycemic state in patients with uncontrolled diabetes.
• Volume overload in patients with heart failure leading to pulmonary edema.
• Metabolic acidosis secondary to rapid glucose metabolism in susceptible individuals.

Before using Glucoză Zentiva, healthcare professionals should evaluate patient-specific factors and monitor for potential complications.

• Assess blood glucose levels prior to infusion and adjust rate to avoid excessive hyperglycemia.
• Review cardiac and renal function, especially in patients at risk for fluid overload.
• Use caution in individuals with known hypersensitivity to glucose solutions or any excipients.
• Monitor electrolytes, particularly sodium and potassium, during and after administration.
• Avoid rapid infusion rates exceeding recommended limits to reduce risk of osmotic shifts.
• Consider alternative carbohydrate sources in patients with severe diabetes mellitus.

Glucoză Zentiva may interact with other intravenous therapies or medications that affect glucose metabolism, fluid balance, or electrolyte status.

Avoid

• Concurrent administration with high‑dose insulin infusions without appropriate glucose monitoring.
• Co‑infusion of hypertonic saline solutions that could exacerbate hyperosmolarity.
• Use together with other carbohydrate‑containing parenteral solutions unless total glucose load is calculated.

Use with caution

• Simultaneous use with diuretics, especially loop diuretics, may increase risk of electrolyte disturbances.
• Combination with vasopressors may require careful volume management to avoid overload.
• Patients receiving total parenteral nutrition should have the glucose contribution from Glucoză Zentiva accounted for in the overall caloric calculation.